Novartis Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 9/20/2026)
| Balance Sheet | Total Assets | 115,569,000,000.00 | ROE | 39.92 % |
| Balance Sheet | Total Equity | 92,679,000,000.00 | ROA | 12.10 % |
| Cashflow | Capital Expenditures | -1,555,930,000.00 | P/FCF | 16.33 |
| Cashflow | Free Cash Flow | 17,588,070,400.00 | – | – |
| Cashflow | Operating Cash Flow | 19,144,000,000.00 | P/CF | 15.00 |
| Income | Earnings per Share (diluted) | 7.15 | Div. Yield | 3.18 % |
| Income | Net Income | 13,984,000,000.00 | P/E | 20.54 |
| Income | Shares Outstanding | 1,955,000,000.00 | P/B | 6.22 |
| Income | Total Revenue | 57,998,000,000.00 | P/S | 5.24 |
Ratios calculated on: 10/14/2026
Company Description
Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company's segments include Pharmaceuticals, Alcon and Sandoz. Its Pharmaceuticals segment is engaged in researching, developing, manufacturing, distributing and selling patented prescription medicines in the therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience and established medicines. Its Alcon segment is engaged in developing, manufacturing and selling eye care products across the world. Its Sandoz segment is engaged in developing, manufacturing and marketing generic pharmaceutical products, follow-on biopharmaceutical products known as biosimilars and drug substances that are not protected by valid and enforceable third-party patents.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.novartis.de
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more